Tech Company Financing Transactions
MiroBio Funding Round
MiroBio closed a $97 million Series B funding round on 6/29/2022. Investors included Medicxi Ventures, Advent Life Sciences and OrbiMed.
Transaction Overview
Company Name
Announced On
6/29/2022
Transaction Type
Venture Equity
Amount
$97,000,000
Round
Series B
Investors
Medicxi Ventures (Lead Investor) (Nick Williams)
OrbiMed (Erez Chimovits)
Samsara BioCapital (Srini Akkaraju)
Proceeds Purpose
Funds will primarily be used to advance MiroBio's two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Winchester House Heatley Road Oxford Science Park
Oxford, OX4 4GE
UK
Oxford, OX4 4GE
UK
Phone
Website
Email Address
Overview
MiroBio is a private biotechnology company formed out of Oxford University and backed by a strong group of international investors: Medicxi, OrbiMed, Oxford Science Enterprises, Samsara BioCapital, SR One, Advent Life Sciences and Monograph.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Eliot Charles
Chief Medical Officer
Sanjay Keswani
Chief Scientific Officer
Lynne Murray
Browse more venture capital transactions:
Prev: 6/28/2022: Audience.co venture capital transaction
Next: 6/29/2022: Kukua venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs